Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA

Tuesday, May 9, 2017 11:02 AM UTC

ADVISORY, May 09, 2017 --

WHO:	Emergent BioSolutions Inc. (NYSE:EBS)

WHAT:	Ribbon-cutting and tour of expanded Emergent BioSolutions’ Center for
	Innovation in Advancement Development and Manufacturing (CIADM),
	featuring speakers:

	Daniel J. Abdun-Nabi
	President & Chief Executive Officer, Emergent BioSolutions

	Rick A. Bright, Ph.D.
	Director, Biomedical Advanced Research and Development Authority (BARDA)
	Deputy Assistant Secretary, Office of the Assistant Secretary for Preparedness
	and Response at the U.S. Department of Health and Human Services (HHS)

	William H. Cole
	President & CEO, Baltimore Development Corporation

	Secretary Mike Gill
	Department of Commerce, State of Maryland

WHY:	Five years ago, Emergent and BARDA entered into a public-private partnership
	to establish a CIADM intended to develop and manufacture medical
	countermeasures to protect the public in health emergencies.

	This Wednesday, Emergent will unveil its newly expanded Baltimore CIADM
	facility – one of only three HHS-designated Centers in the United States. The
	112,000-square-foot facility, comprised of laboratory, manufacturing and office
	space, offers flexible manufacturing of drug substance from microbial, cell
	culture, or viral production platforms. Its capabilities for advanced
	development and manufacturing of medical countermeasures were designed to
	help address the U.S. government’s national security and public health needs.
	The facility is equipped with disposable manufacturing technology to enable
	Emergent to meet the government’s domestic preparedness priorities and
	needs on a cost-effective, reliable and sustainable basis.

	Since its inception, the Emergent CIADM has been awarded four task orders by
	BARDA to develop Ebola and Marburg therapeutics and a Zika vaccine.
	Emergent has also successfully manufactured some of its product candidates
	at the CIADM and an Ebola vaccine candidate as part of a third-party
	collaboration.

WHERE:	Emergent BioSolutions Bayview Campus
	5901 East Lombard St.
	Baltimore, MD 21224

WHEN:	Wednesday, May 10, 2017
	9 a.m. to 11 a.m.

About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.

Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
[email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA

Editor's Picks

Welcome to EconoTimes